04:38 AM EST, 12/09/2024 (MT Newswires) -- Agios Pharmaceuticals ( AGIO ) said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals. In the study, mitapivat demonstrated a statistically significant reduction in transfusion burden compared with placebo, the company said. The company...

04:23 AM EST, 12/09/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Sunday that the Darzalex Faspro-based regime significantly improved overall and sustained minimal residual disease negativity rates and progression-free survival in patients with newly diagnosed multiple myeloma. The company said the results were based on expanded data from the phase 3 study and a post hoc analysis...

04:17 AM EST, 12/09/2024 (MT Newswires) -- Arcellx ( ACLX ) said Sunday preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate. Results from the trial at median follow-up of 9.5 months also showed a complete response/stringent complete response rate of 62% with no delayed...

04:43 AM EST, 12/09/2024 (MT Newswires) -- Beam Therapeutics ( BEAM ) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Engraftment is the process under which transplanted stem cells enter the bloodstream,...